Tyrosine kinase inhibitorFDA-approvedSecond-line
Ponatinib
How it works
Blocks the BCR-ABL tyrosine kinase enzyme, which is overactive in CML cells, and also inhibits other tyrosine kinases involved in cancer cell growth.
Cancer types
Leukemia— BCR-ABL-positive
Efficacy
In clinical trials, around 30% of patients with BCR-ABL-positive CML achieved a major cytogenetic response, with a median progression-free survival of approximately 1 year.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Ponatinib for Pediatric Cancer Treatment | Leukemia | phase-1 | — | Source → |
| Testing Treatments for Pancreatic Cancer in Lab Models | Pancreatic Cancer | phase-2 | — | Source → |
| Study of Decitabine, Venetoclax, and Ponatinib for Leukemia Treatment | Leukemia | phase-2 | — | Source → |
| Testing a Combination of Medications for Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Asciminib Study for CML Patients Resistant to Ponatinib | Leukemia | phase-2 | — | Source → |
| Combination Chemotherapy and Ponatinib Hydrochloride in Treating Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Combination Therapy for CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Evaluating Ponatinib Hydrochloride for Chronic Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Combining Ponatinib and Vitamin K2 May Help Treat Acute Myeloid Leukemia | Leukemia | lab-study | — | Source → |
| Choosing the Right Second-Line Treatment for Chronic Myeloid Leukemia | Leukemia | review | — | Source → |
| Ponatinib Improves Quality of Life for Leukemia Patients | Leukemia | phase-3 | — | Source → |
| Ponatinib-based therapy shows promise for CML in myeloid blast phase | Leukemia | phase-2 | The rate of morphological remission with or without count recovery (i.e. overall response rate [ORR]) was 49%. | Source → |
| Combining Two Leukemia Treatments Shows Promise in Lab Experiments | Leukemia | lab-study | — | Source → |
| Combining Ponatinib and Blinatumomab in Leukemia Treatment | Leukemia | phase-2 | The complete molecular response rate was 83% and the rate of measurable residual disease negativity was 98%. | Source → |
| BCR::ABL1 Inhibitors Affect Blood Vessel Growth Differently | Leukemia | lab-study | — | Source → |
| New Study Compares Treatments for a Specific Type of Leukaemia | Leukemia | phase-3 | — | Source → |
| Comparing Ponatinib Doses for Chronic Myeloid Leukemia | Leukemia | meta-analysis | 45 mg ponatinib was superior to other doses of ponatinib and other TKIs in CCyR, MCyR and CHR. | Source → |
| Ponatinib's Long-Term Effects in Chronic Myeloid Leukemia Patients | Leukemia | observational | The estimated 2-year progression-free survival was 84%. | Source → |
| CAR-T Cells and Ponatinib Help Leukemia Patient | Leukemia | observational | — | Source → |
| Ponatinib Shows Promise as Third-Line Treatment for Chronic Myeloid Leukemia | Leukemia | observational | The 3-year progression-free survival was 59% with 2G-TKI and 83% with ponatinib. | Source → |
| Ponatinib and Dasatinib Compared in Leukemia Patients with Brain Relapse | Leukemia | observational | The total CR (complete remission) rate was 90.5%. | Source → |
| Safer Version of Cancer Drug Ponatinib Developed | Leukemia | lab-study | The new compounds showed a larger therapeutic window in vivo, leading to regression of human T315I mutant CML xenografts without cardiotoxicity. | Source → |
| Real-World Study of Ponatinib Treatment for Chronic Myeloid Leukaemia | Leukemia | observational | A molecular response was reported for 59% of patients. | Source → |
| Ponatinib Effective in Some Pediatric Leukemia Patients | Leukemia | observational | Six patients with Ph+ ALL and two with CML responded to ponatinib. | Source → |
| Combining Herbal Extract with Leukemia Drug Shows Promise | Leukemia | lab-study | OSM reduced the ponatinib dose ∼5-fold. | Source → |
| Ponatinib Affects Platelet Function in Leukemia Patients | Leukemia | lab-study | — | Source → |
| Ponatinib May Improve Outcomes for Leukemia Patients | Leukemia | observational | The 5-year progression-free survival and overall survival rates were 68% and 72%, respectively. | Source → |
| Similar Heart Risks for Two Leukemia Treatments | Leukemia | observational | Ponatinib and bosutinib was associated with similar incidence and risk of CV events, including MACEs (HR: 1.02; 95% CI: 0.35, 3.01), AOEs (HR: 0.90; 95% CI: 0.43, 1.85) and VOEs (HR: 0.92; 95% CI: 0.44, 1.94). | Source → |
| Ponatinib vs Imatinib for Leukemia Treatment: Cost Comparison | Leukemia | phase-3 | Ponatinib offered an approximate gain of 3 months of life and 6 months of quality-adjusted life. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.